Your browser doesn't support javascript.
loading
Quality control in the Netherlands; todays practices and starting points for guidance and future research.
van Rossum, Huub H; van Schrojenstein Lantman, Marith; Severens, Michel; Vermeer, Henricus J; Verboeket-van de Venne, Wilhelmine P H G; Oosterhuis, Wytze; de Jonge, Niels.
Afiliação
  • van Rossum HH; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Schrojenstein Lantman M; Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Severens M; Department of Clinical Chemistry and Hematology, 2998 Result Laboratorium, Albert Schweitzer Hospital , Dordrecht, The Netherlands.
  • Vermeer HJ; SKML, Organization for Quality Assurance of Medical Laboratory Diagnostics, Radboud University, Nijmegen, The Netherlands.
  • Verboeket-van de Venne WPHG; SSSS, Maastricht, The Netherlands.
  • Oosterhuis W; Department of Clinical Chemistry and Hematology, 2998 Result Laboratorium, Albert Schweitzer Hospital , Dordrecht, The Netherlands.
  • de Jonge N; Department of Clinical Chemistry and Hematology, 3802 Zuyderland Medical Centre , Sittard-Geleen/Heerlen, The Netherlands.
Clin Chem Lab Med ; 62(11): 2177-2184, 2024 Oct 28.
Article em En | MEDLINE | ID: mdl-38661089
ABSTRACT

OBJECTIVES:

Adequate analytical quality of reported results is primarily ensured by performing internal quality control (iQC). Currently, several different iQC practices are in use. As a prelude to the revision of a Dutch guidance document on analytical QC, a questionnaire was sent out to gain insights in the applied practices and the need for guidance.

METHODS:

A questionnaire, containing 20 multiple-choice questions with possibilities for explanation and comment on iQC practices and aspects was distributed to all clinical chemistry laboratories within the Netherlands. Results were reported descriptively.

RESULTS:

Responses were received from 27 clinical laboratories (response 43 %). In 30 % the iQC was based on the analytical characteristics only, while 30 % used a 6-Sigma method, 19 % risk-based beyond 6-Sigma and 22 % used an alternative approach. 89 % of laboratories used a virtual analyzer model for iQC setup within one or more laboratory sites. Practices for determining standard deviation (SD) values included determining SD for each new iQC material (35 %), using historical SD values for new materials (35 %), and incorporating clinical tolerances into the SD value (31 %). Furthermore, 44 % of laboratories used patient moving averages for one or more tests. Daily iQC management was based on either "traffic lights" indicating in or out of control status, and review of all QC charts, often using multiple software systems.

CONCLUSIONS:

A large heterogeneity of iQC practices in clinical laboratories was observed in the Netherlands. Several starting points for further research and/or guidance were identified, particularly in relation to the determination of SD values, the virtual analyzer model and methods to ensure analyzer equivalence.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article